3-[6-[2-Amino-4-(trifluoromethyl)pyrimidin-5-yl]-2-morpholin-4-ylpyrimidin-4-yl]-4-ethyl-5-phenyl-1,3-oxazolidin-2-one

• 分子结构分类: 有机化合物 - 有机氮化合物
• 英文名称: 3-[6-[2-Amino-4-(trifluoromethyl)pyrimidin-5-yl]-2-morpholin-4-ylpyrimidin-4-yl]-4-ethyl-5-phenyl-1,3-oxazolidin-2-one
• 英文别名: 3-[6-[2-amino-4-(trifluoromethyl)pyrimidin-5-yl]-2-morpholin-4-ylpyrimidin-4-yl]-4-ethyl-5-phenyl-1,3-oxazolidin-2-one
• 化学式: C₂₄H₂₄F₃N₇O₃
• 分子量: 515.5
• InChiKey: QPCPSPSSGSDMCQ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.2
• 重原子数：
  37
• 可旋转键数：
  5
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.38
• 拓扑面积：
  120
• 氢给体数：
  1
• 氢受体数：
  12

文献信息

• OXAZOLIDIN-2-ONE-PYRIMIDINE DERIVATIVES FOR USE IN THE TREATMENT OF SKIN FIBROSIS, SCLERODERMA, HYPERTROPHIC SCARS OR KELOIDS
  申请人：Novartis AG

  公开号：EP3199158A1

  公开（公告）日：2017-08-02

  The present invention relates to oxazolidin-2-one substituted pyrimidine compounds that act as PI3K (phosphatidylinositol-3-kinase) inhibitors, as well as pharmaceutical compositions thereof, methods for their manufacture and uses for the treatment of conditions, diseases and disorders dependent on PI3K.

  本发明涉及作为 PI3K（磷脂酰肌醇-3-激酶）抑制剂的噁唑烷-2-酮取代的嘧啶化合物，以及其药物组合物、制造方法和用于治疗依赖于 PI3K 的病症、疾病和失调的用途。
• Oxazolidin-2-one-pyrimidine derivatives and the use thereof as phosphatidylinositol-3-kinase inhibitors
  申请人：Novartis AG

  公开号：US10202371B2

  公开（公告）日：2019-02-12

  The present invention relates to oxazolidin-2-one substituted pyrimidine compounds that act as PI3K (phosphatidylinositol-3-kinase) inhibitors, as well as pharmaceutical compositions thereof, methods for their manufacture and uses for the treatment of conditions, diseases and disorders dependent on PI3K.

  本发明涉及作为 PI3K（磷脂酰肌醇-3-激酶）抑制剂的噁唑烷-2-酮取代的嘧啶化合物，以及其药物组合物、制造方法和用于治疗依赖于 PI3K 的病症、疾病和失调的用途。
• OXAZOLIDIN-2-ONE-PYRIMIDINE DERIVATIVES
  申请人：Novartis AG

  公开号：EP2922848A1

  公开（公告）日：2015-09-30
• [EN] OXAZOLIDIN-2-ONE-PYRIMIDINE DERIVATIVES<br/>[FR] DÉRIVÉS D'OXAZOLIDIN-2-ONE-PYRIMIDINE
  申请人：NOVARTIS AG

  公开号：WO2014072956A1

  公开（公告）日：2014-05-15

  The present invention relates to oxazolidin-2-one substituted pyrimidine compounds that act as PI3K (phosphatidylinositol-3-kinase) inhibitors, as well as pharmaceutical compositions thereof, methods for their manufacture and uses for the treatment of conditions, diseases and disorders dependent on PI3K.